Lyell Immunopharma, Inc. Shareholders' Equity
Lyell Immunopharma, Inc. (LYEL) had Shareholders' Equity of $233.81 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:StockholdersEquity · last filed 2026-08-06
- 2026-06-30: Stockholders' Equity Attributable to Parent $233.81M.
- 2026-03-31: Stockholders' Equity Attributable to Parent $273.67M.
- 2025-12-31: Stockholders' Equity Attributable to Parent $248.20M.
- 2025-09-30: Stockholders' Equity Attributable to Parent $329.12M.
| Period end | Stockholders' Equity Attributable to Parent |
|---|---|
| 2026-06-30 | $233.81M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $273.67M 10-Q · filed 2026-08-06 |
| 2025-12-31 | $248.20M 10-Q · filed 2026-08-06 |
| 2025-09-30 | $329.12M 10-Q · filed 2025-11-12 |
| 2025-06-30 | $298.92M 10-Q · filed 2026-08-06 |
| 2025-03-31 | $336.52M 10-Q · filed 2026-08-06 |
| 2024-12-31 | $382.82M 10-Q · filed 2026-08-06 |
| 2024-09-30 | $530.70M 10-Q · filed 2025-11-12 |
| 2024-06-30 | $566.50M 10-Q · filed 2025-11-12 |
| 2024-03-31 | $603.16M 10-Q · filed 2025-08-12 |
| 2023-12-31 | $654.95M 10-K · filed 2026-03-12 |
| 2023-09-30 | $697.57M 10-Q · filed 2024-11-07 |
| 2023-06-30 | $736.86M 10-Q · filed 2024-11-07 |
| 2023-03-31 | $783.83M 10-Q · filed 2024-08-07 |
| 2022-12-31 | $833.25M 10-K · filed 2026-03-12 |
| 2022-09-30 | $820.03M 10-Q · filed 2023-11-07 |
| 2022-06-30 | $868.04M 10-Q · filed 2023-11-07 |
| 2022-03-31 | $881.25M 10-Q · filed 2023-08-08 |
| 2021-12-31 | $929.79M 10-K · filed 2025-03-11 |
| 2021-09-30 | $986.47M 10-Q · filed 2022-11-08 |
| 2021-06-30 | $1.02B 10-Q · filed 2022-11-08 |
| 2021-03-31 | -$334.05M 10-Q · filed 2022-08-04 |
| 2020-12-31 | -$292.53M 10-K · filed 2024-02-28 |
| 2020-09-30 | -$266.64M 10-Q · filed 2021-11-12 |
| 2020-06-30 | -$240.11M 10-Q · filed 2021-11-12 |
| 2020-03-31 | -$150.83M 10-Q · filed 2021-08-12 |
| 2019-12-31 | -$111.11M 10-K · filed 2023-02-28 |
| 2018-12-31 | $850.00K 10-K · filed 2022-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |